CTRI/2021/05/033314尚未招募2 期
An open-label, single-arm clinical study to evaluateefficacy, safety and tolerability of tacrolimus lipid suspension for ophthalmic drops in adult patients of allergic conjunctivitis refractory to standard treatment
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Clinical diagnosis of bilateral allergic conjunctivitis (AC) made by an experienced ophthalmologist following recording of symptoms based on complete ophthalmic examination as per standard clinical practice using determination of visual acuity, slit-lamp biomicroscopy and indirect ophthalmoscopy, whenever required.
- •2. Not responsive to treatment with first line therapeutic agents for sufficient duration as per the best discretion of the Investigator which must include cold compress, artificial tears, topical over the counter preparations, anti-histaminics, mast cell stabilizers and / or topical corticosteroids depending upon the severity of disease
- •3. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at the start of treatment.
- •4. Surgically sterile, post-menopausal, or sexually abstinent patient or partner must agree to use a medically appropriate form of birth control from screening until 14 + 2 day after the last dose of study medication.
- •5. The patients who are able to understand and sign a written informed consent form, which is obtained prior to initiation of study procedures.
排除标准
- •1.Presence of co-existing ocular diseases such as glaucoma, dry eye syndrome, uveitis, ocular infection.
- •2.Presence of systemic diseases other than co-existing allergic rhinitis, asthma and atopic dermatitis.
- •3.Patient with ocular structural abnormalities like lid scarring, entropion, trichiasis, etc.
- •4.Reported hypersensitivity to Tacrolimus or cyclosporine or have a history of serious AEs related to their use.
- •5.Patients wearing contact lenses.
- •6.Patients who could not discontinue receiving ocular vasoconstrictor and ocular nonsteroidal anti-inflammatory drugs at the start of study drug administration.
- •7.Patients who underwent cryosurgery or surgical excision of giant papillae of the eye(s) to which the study drug was to be instilled within 4 weeks prior to the start of study drug administration.
- •8.Patients who were receiving desensitization therapy or immune modulation therapy in any form 4 weeks prior to the start of study drug administration.
- •9.Patients who had cataract as a complication in the eye(s) to which the study drug was/were to be instilled, making it impossible to perform fundoscopy by mydriasis.
- •10.Expecting mothers, lactating mothers, or women wishing to become pregnant.
- •11.Patients with malignant tumors either as a concomitant disease or a history. (Patients in whom malignant tumors had not recurred more than for 10 years are eligible).
- •12.Patients with systemic infectious disease.
- •13.Patients who are receiving treatment requiring hospitalization.
- •14.History of chemical substance abuse.
- •15.Patients with repeated anti-inflammatory drug treatment
- •16.Any condition which the study physician judges to preclude safe participation in the study or to confound the evaluation of the study outcome.
- •17.Patients who had participated in any other clinical or post-marketing studies (not only for study drugs but also for medical devices) before 60 days from the day of screening.
研究者
相似试验
尚未招募
Unknown
A Clinical trial of Malbet syrup in pediatric patients with uncomplicated influenza.CTRI/2023/10/058221Solar Herbo Pvt. Ltd.
尚未招募
3 期
To know the effect of Rumalaya cream in common muscular paiCTRI/2021/11/038256Himalaya Wellness Company
已完成
2 期
A clinical study of two formulations, navakashaya and vidangadi lepa in patients with vicharchika(dermatitis).CTRI/2022/05/042516Sri Dharmasthala Manjunatheswara College of Ayurveda and Hospital30
尚未招募
不适用
Evaluation of Safety and Tolerability of Purim Tablet in Healthy PeopleCTRI/2022/06/043510Himalaya Wellness Company
尚未招募
1 期
Evaluate the Safety and Tolerability of HHIC-102107 Capsules in Healthy AdultsCTRI/2023/03/051067Himalaya Wellness Company